Diana Ghelber
Psychiatry · Fort Worth, TXNPI 1962720144
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,581 of the $6,653 with a category attached, or 68.9%. 22 manufacturers reported payments, led by Johnson & Johnson at 36.4% of the total. Reporting peaked in 2020 at $3,374 and has fallen 85.3% since, to $495 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $42.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Brainsway USA Inc$2K
- Otsuka America Pharmaceutical, Inc.$365
- Alkermes, Inc.$357
- Teva Pharmaceuticals USA, Inc.$356
- Sunovion Pharmaceuticals Inc.$270
- plus $1K from 16 others
Across 111 payments — averaging $17,155 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$803K
- Janssen Research & Development, LLC$801K
- Boehringer Ingelheim$205K
- Biohaven Pharmaceutical Holding Company Ltd.$44K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$26K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$14K
- plus $12K from 3 others
What the payments were for
- Consulting fees$2,00030%
- Food & beverage$4,58169%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 12 | $2,421 |
| Brainsway USA Inc | 2 | $1,794 |
| Otsuka America Pharmaceutical, Inc. | 14 | $365 |
| Alkermes, Inc. | 6 | $357 |
| Teva Pharmaceuticals USA, Inc. | 23 | $356 |
| Sunovion Pharmaceuticals Inc. | 24 | $270 |
| Bausch Health US, LLC | 23 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $199 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $173 |
| Neurocrine Biosciences, Inc. | 7 | $141 |
| AbbVie | 7 | $110 |
| Lundbeck LLC | 3 | $61 |
| Adlon Therapeutics L.p. | 3 | $44 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Biogen | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $16 |
| Corium, LLC | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$2,250
- Brainsway Deep TMS System$1,692
- LYBALVI$966
- REXULTI$207
- Deep TMS System$102
How this compares
$6,653 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 18 | $165,820 |
| TrintellixVortioxetine Hydrobromide | 28 | $21,472 |
| Duloxetine Hcl | 134 | $3,575 |
| Trazodone Hcl | 165 | $2,576 |
| Clozapine | 30 | $2,487 |
| RitalinMethylphenidate Hcl | 18 | $2,398 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 42 | $2,338 |
| Buspirone Hcl | 115 | $2,323 |
| Bupropion XlBupropion Hcl | 91 | $1,881 |
| Gabapentin | 81 | $1,789 |
| Aripiprazole | 45 | $1,766 |
| Clonazepam | 182 | $1,649 |
| Vilazodone Hcl | 17 | $1,363 |
| Mirtazapine | 66 | $1,363 |
| Escitalopram Oxalate | 83 | $1,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $356 | $165,82018 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $199 | $21,47228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Fort Worth
- Andrew KimFort Worth$162K
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.